Southern California Bancorp BCAL 深 沪
已收盘 08-01 16:00:00 美东时间
14.60
-0.390
-2.60%
华盛通- 最 高14.91
- 今 开14.87
- 成交量 15.28万股
- 最 低 14.56
- 昨 收 14.99
- 总市值 4.73亿
- 52周最高 18.49
- 市盈率 静 66.18
- 换手率 0.47%
- 52周最低 11.87
- 委 比 86.85%
- 总股本 3241.29万
- 历史最高 18.49
- 量 比 1.06
- 振 幅 2.33%
- 历史最低 11.87
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BCAL Diagnostics Expands BREASTEST plus™ Rollout Amid Growing Clinical Recognition
The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCA...
07-30 07:57
Stephens & Co. Maintains Equal-Weight on California BanCorp, Raises Price Target to $19
Stephens & Co. analyst Andrew Terrell maintains California BanCorp (NASDAQ:BCAL) with a Equal-Weight and raises the price target from $18 to $19.
07-29 21:19
Southern Calif Bancorp Q2 EPS $0.43 Beats $0.41 Estimate, Sales $44.273M Miss $44.786M Estimate
Southern Calif Bancorp (NASDAQ:BCAL) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.41 by 5.65 percent. This is a 104.76 percent increase over earnings of $0.21 per share
07-28 20:10
BCAL Diagnostics Expands BREASTEST plus Access in Sydney and Melbourne
BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics...
05-06 10:07
California BanCorp. increases size of share repurchase program
California BanCorp. (NASDAQ:BCAL) announced on Thursday an increase to the size of its share repurchase program to 1.6M shares from 550K shares. The board of the bank holding company authorized it to ...
05-02 21:04
Southern California Bancorp Expands Share Repurchase Program
An update from Southern California Bancorp ( ($BCAL) ) is now available. On May...
05-02 05:28
Southern California Bancorp Delays Yearly Report Filing
Southern California Bancorp ( ($BCAL) ) has released a notification of late fil...
03-18 06:20
BCAL Diagnostics Reports Increased Losses Amidst Strategic Expansion
An update from BCAL Diagnostics Limited ( ($AU:BDX) ) is now available. BCAL Di...
02-28 08:28
美股大行评级 | 大行唱多CING再涨340%！CORT获上调目标价至1320美元
Oppenheimer：上调Ovid Therapeutics(OVID)评级至"跑赢大市"，目标价4美元
01-31 15:37
